These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144 [TBL] [Abstract][Full Text] [Related]
15. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure. Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376 [TBL] [Abstract][Full Text] [Related]
16. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Gupta N; Wakefield DN; Clapp WL; Garin EH Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516 [TBL] [Abstract][Full Text] [Related]
17. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601 [TBL] [Abstract][Full Text] [Related]
18. C3 glomerulopathies. A new perspective on glomerular diseases. Rabasco-Ruiz C; Huerta-Arroyo A; Caro-Espada J; Gutiérrez-Martínez E; Praga-Terente M Nefrologia; 2013; 33(2):164-70. PubMed ID: 23511752 [TBL] [Abstract][Full Text] [Related]
19. Treatment of C3 glomerulopathy with complement blockers. Vivarelli M; Emma F Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307 [TBL] [Abstract][Full Text] [Related]